Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 6/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328621 | 0.93 | HSD11B1 (0.37) | HTR2CSLC6A4HSD11B1NR1H4UBE2M | |
| SCHEMBL3329038 | 0.90 | LNPEP (0.37) | UBE2MDCUN1D1LNPEPLMNATSHR | |
| SCHEMBL3327472 | 0.88 | HSD11B1 (0.37) | HTR2CSLC6A4HSD11B1NR1H4UBE2M | |
| SCHEMBL5747485 | 0.84 | HSD11B1 (0.45) | HSD11B1NR1H4LNPEPNPSR1RAB9A | |
| SCHEMBL13167708 | 0.83 | LMNA (0.46) | HSD11B1UBE2MDCUN1D1LMNA | |
| SCHEMBL19470003 | 0.82 | KCNH2 (0.33) | HTR2CSLC6A4HSD11B1NR1H4 | |
| SCHEMBL3367039 | 0.82 | LMNA (0.34) | HTR2CSLC6A4UBE2MDCUN1D1LNPEP | |
| SCHEMBL10313823 | 0.79 | HSD11B1 (0.41) | HTR2CSLC6A4HSD11B1NR1H4UBE2M | |
| SCHEMBL11999874 | 0.78 | HSD11B1 (0.38) | HSD11B1NR1H4UBE2MDCUN1D1LMNA | |
| SCHEMBL2799351 | 0.76 | PIK3CA (0.37) | HTR2CHSD11B1NR1H4LMNAKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-2137196-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-2137196-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008128942-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | HTR2C 587/4885SLC6A4 603/4885HSD11B1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.